Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Influenza

  Free Subscription


Articles published in J Gen Virol

Retrieve available abstracts of 49 articles:
HTML format



Single Articles


    November 2021
  1. SEALY JE, Howard WA, Molesti E, Iqbal M, et al
    Amino acid substitutions in the H5N1 avian influenza haemagglutinin alter pH of fusion and receptor binding to promote a highly pathogenic phenotype in chickens.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  2. ORR-BURKS N, Murray J, Todd KV, Bakre A, et al
    MicroRNAs affect GPCR and Ion channel genes needed for influenza replication.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  3. VIANA K, Zarpelon L, Leandro A, Terencio M, et al
    Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


    October 2021
  4. HUSSAIN S, Daniels RS, Wharton SA, Howell S, et al
    Reduced sialidase activity of influenza A(H3N2) neuraminidase associated with positively charged amino acid substitutions.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  5. MHAMDI Z, Carbonneau J, Venable MC, Baz M, et al
    Replication and transmission of an influenza A(H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  6. OLBRICH L, Castelletti N, Schalte Y, Gari M, et al
    Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


    September 2021
  7. STALLER E, Sheppard CM, Baillon L, Frise R, et al
    A natural variant in ANP32B impairs influenza virus replication in human cells.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


    August 2021
  8. HIRST JC, Hutchinson EC
    Corrigendum: Single-particle measurements of filamentous influenza virions reveal damage induced by freezing.
    J Gen Virol. 2021;102.
    PubMed    


  9. RAHMAN F, Libre C, Oleinikov A, Tcherniuk S, et al
    Chloroquine and pyrimethamine inhibit the replication of human respiratory syncytial virus A.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


    July 2021
  10. POHL MO, Busnadiego I, Marrafino F, Wiedmer L, et al
    Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


    June 2021
  11. ELGENDY EM, Arai Y, Kawashita N, Isobe A, et al
    Double mutations in the H9N2 avian influenza virus PB2 gene act cooperatively to increase viral host adaptation and replication for human infections.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  12. CHAPPELL JG, Tsoleridis T, Clark G, Berry L, et al
    Retrospective screening of routine respiratory samples revealed undetected community transmission and missed intervention opportunities for SARS-CoV-2 in the United Kingdom.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


    May 2021
  13. DISSANAYAKE TK, Yan B, Ng AC, Zhao H, et al
    Differential role of sphingomyelin in influenza virus, rhinovirus and SARS-CoV-2 infection of Calu-3 cells.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  14. GOLDEN JW, Zeng X, Cline CR, Garrison AR, et al
    Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  15. ZHANG QY, Deng CL, Liu J, Li JQ, et al
    SARS-CoV-2 replicon for high-throughput antiviral screening.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


    April 2021
  16. HENSS L, Auste A, Schurmann C, Schmidt C, et al
    The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  17. SMITHER SJ, Eastaugh LS, Findlay JS, Laws TR, et al
    Investigative study into whether an insect repellent has virucidal activity against SARS-CoV-2.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  18. PEACOCK TP, Penrice-Randal R, Hiscox JA, Barclay WS, et al
    SARS-CoV-2 one year on: evidence for ongoing viral adaptation.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  19. DAVIES K, Buczkowski H, Welch SR, Green N, et al
    Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


    March 2021
  20. MONCHATRE-LEROY E, Lesellier S, Wasniewski M, Picard-Meyer E, et al
    Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  21. GUPTA A, Sabarinathan R, Bala P, Donipadi V, et al
    A comprehensive profile of genomic variations in the SARS-CoV-2 isolates from the state of Telangana, India.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  22. ROE MK, Junod NA, Young AR, Beachboard DC, et al
    Targeting novel structural and functional features of coronavirus protease nsp5 (3CL(pro), M(pro)) in the age of COVID-19.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  23. AUERSWALD H, Yann S, Dul S, In S, et al
    Assessment of inactivation procedures for SARS-CoV-2.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


  24. SIMMONDS P, Williams S, Harvala H
    Understanding the outcomes of COVID-19 - does the current model of an acute respiratory infection really fit?
    J Gen Virol. 2021;102.
    PubMed     Abstract available


    February 2021
  25. KHALIL AM, Yoshida R, Masatani T, Takada A, et al
    Variation in the HA antigenicity of A(H1N1)pdm09-related swine influenza viruses.
    J Gen Virol. 2021 Feb 22. doi: 10.1099/jgv.0.001569.
    PubMed     Abstract available


  26. CLEMENTS AL, Peacock TP, Sealy JE, Lee HM, et al
    PA-X is an avian virulence factor in H9N2 avian influenza virus.
    J Gen Virol. 2021 Feb 5. doi: 10.1099/jgv.0.001531.
    PubMed     Abstract available


    January 2021
  27. KIM DI, Cho YB, Lim Y, Hong SH, et al
    Chios mastic gum inhibits influenza A virus replication and viral pathogenicity.
    J Gen Virol. 2021 Jan 8. doi: 10.1099/jgv.0.001550.
    PubMed     Abstract available


  28. THAKUR N, Conceicao C, Isaacs A, Human S, et al
    Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell-cell fusion.
    J Gen Virol. 2021;102.
    PubMed     Abstract available


    December 2020
  29. HARRIS M
    Microbiology Society online workshop on SARS-CoV-2 and COVID-19, Wednesday 29 July 2020.
    J Gen Virol. 2020;101:1227-1228.
    PubMed    


    November 2020
  30. YU J, Li F, Wang D
    The first decade of research advances in influenza D virus.
    J Gen Virol. 2020 Nov 19. doi: 10.1099/jgv.0.001529.
    PubMed     Abstract available


  31. KLIMSTRA WB, Tilston-Lunel NL, Nambulli S, Boslett J, et al
    SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients.
    J Gen Virol. 2020;101:1156-1169.
    PubMed     Abstract available


    October 2020
  32. LI Y, Chai W, Min J, Ye Z, et al
    Neddylation of M1 negatively regulates the replication of influenza A virus.
    J Gen Virol. 2020 Oct 5. doi: 10.1099/jgv.0.001503.
    PubMed     Abstract available


  33. FIRTH AE
    A putative new SARS-CoV protein, 3c, encoded in an ORF overlapping ORF3a.
    J Gen Virol. 2020;101:1085-1089.
    PubMed     Abstract available


  34. SILVA SJRD, Germano Mendes RP, Alves da Silva CT, Lorusso A, et al
    Insights into SARS-CoV-2, the Coronavirus Underlying COVID-19: Recent Genomic Data and the Development of Reverse Genetics Systems.
    J Gen Virol. 2020;101:1021-1024.
    PubMed     Abstract available


  35. RENNICK LJ, Nambulli S, Lemon K, Olinger GY, et al
    Recombinant subtype A and B human respiratory syncytial virus clinical isolates co-infect the respiratory tract of cotton rats.
    J Gen Virol. 2020;101:1056-1068.
    PubMed     Abstract available


  36. RIJSBERGEN LC, Rennick LJ, Laksono BM, van Run PRWA, et al
    In vivo comparison of a laboratory-adapted and clinical-isolate-based recombinant human respiratory syncytial virus.
    J Gen Virol. 2020;101:1037-1046.
    PubMed     Abstract available


    September 2020
  37. MOOIJ P, Mortier D, Stammes M, Fagrouch Z, et al
    Aerosolized pH1N1 influenza infection induces less systemic and local immune activation in the lung than combined intrabronchial, nasal and oral exposure in cynomolgus macaques.
    J Gen Virol. 2020 Sep 25. doi: 10.1099/jgv.0.001489.
    PubMed     Abstract available


  38. WANG J, Xu X, Zhou X, Chen P, et al
    Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection.
    J Gen Virol. 2020;101:921-924.
    PubMed     Abstract available


    August 2020
  39. KELLAM P, Barclay W
    The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection.
    J Gen Virol. 2020;101:791-797.
    PubMed     Abstract available


    June 2020
  40. ZHANG T, Fan K, Zhang X, Xu Y, et al
    Diversity of avian influenza A(H5N6) viruses in wild birds in southern China.
    J Gen Virol. 2020 Jun 10. doi: 10.1099/jgv.0.001449.
    PubMed     Abstract available


    May 2020
  41. MAO L, Liang P, Li W, Zhang S, et al
    Exosomes promote caprine parainfluenza virus type 3 infection by inhibiting autophagy.
    J Gen Virol. 2020 May 19. doi: 10.1099/jgv.0.001424.
    PubMed     Abstract available


  42. MAJID NN, Omar AR, Mariatulqabtiah AR
    Negligible effect of chicken cytokine IL-12 integration into recombinant fowlpox viruses expressing avian influenza virus neuraminidase N1 on host cellular immune responses.
    J Gen Virol. 2020 May 19. doi: 10.1099/jgv.0.001428.
    PubMed     Abstract available


  43. EIDEN S, Dijkman R, Zell R, Fuchs J, et al
    Using a mouse-adapted A/HK/01/68 influenza virus to analyse the impact of NS1 evolution in codons 196 and 231 on viral replication and virulence.
    J Gen Virol. 2020 May 14. doi: 10.1099/jgv.0.001422.
    PubMed     Abstract available


    April 2020
  44. QIN Z, Qu X, Lei L, Xu L, et al
    Y-Box-Binding Protein 3 (YBX3) Restricts Influenza A Virus by Interacting with Viral Ribonucleoprotein Complex and Imparing its Function.
    J Gen Virol. 2020;101:385-398.
    PubMed     Abstract available


    March 2020
  45. MURR M, Karger A, Steglich C, Mettenleiter TC, et al
    Coexpression of soluble and membrane-bound avian influenza virus H5 by recombinant Newcastle disease virus leads to an increase in antigen levels.
    J Gen Virol. 2020 Mar 25. doi: 10.1099/jgv.0.001405.
    PubMed     Abstract available


    February 2020
  46. BRANTTIE JM, Dutch RE
    Parainfluenza virus 5 fusion protein maintains pre-fusion stability but not fusogenic activity following mutation of a transmembrane leucine/isoleucine domain.
    J Gen Virol. 2020 Feb 25. doi: 10.1099/jgv.0.001399.
    PubMed     Abstract available


    December 2019
  47. TEPPER V, Nykvist M, Gillman A, Skog E, et al
    Influenza A/H4N2 mallard infection experiments further indicate zanamivir as less prone to induce environmental resistance development than oseltamivir.
    J Gen Virol. 2019 Dec 19. doi: 10.1099/jgv.0.001369.
    PubMed     Abstract available


    November 2019
  48. BROWN JC, Barclay WS, Galiano M, Harvey R, et al
    Passage of influenza A/H3N2 viruses in human airway cells removes artefactual variants associated with neuraminidase-mediated binding.
    J Gen Virol. 2019 Nov 8. doi: 10.1099/jgv.0.001348.
    PubMed     Abstract available


    September 2019
  49. HIRST JC, Hutchinson EC
    Single-particle measurements of filamentous influenza virions reveal damage induced by freezing.
    J Gen Virol. 2019 Sep 26. doi: 10.1099/jgv.0.001330.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: